Aurobindo Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on April 06, 2026.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma's Board has approved a share buyback of up to 54,23,728 equity shares (0.93% of paid-up capital) at INR 1,475 per share, totaling up to INR 800 crore. The buyback represents 3.93% and 2.62% of standalone and consolidated free reserves respectively as of March 31, 2025. The buyback will be conducted via the tender offer route and is open to all shareholders including promoters on a proportionate basis. The record date for determining eligible shareholders has been fixed as April 17, 2026. A buyback committee has also been formed to manage the process.
The buyback offers shareholders a 29.5% premium over the face value of INR 1 per share, providing an opportunity to exit at a premium. This is positive for minority shareholders as it signals management confidence in the company's intrinsic value. The buyback will increase promoter holding from 51.82% as promoters are eligible to participate.